AMVUTTRA 25 mg, solution for injection in a pre-filled syringe syringe, 0.5 ml
Active ingredients: Vutrisiran, Vutrisiran sodium
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectionsyringe, 0.5 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- AMVUTTRA 25 mg, solution injectable en seringue préremplie
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 1 seringue(s) préremplie(s) en verre de 0,5 ml avec protège-aiguille
- Marketing authorisation holder
- ALNYLAM NETHERLANDS (PAYS-BAS)
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 6 Feb 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a specialist
- Initial prescription by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
66887122CIP73026049CIP133400930260494Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| VUTRISIRANsolution | 25 mg · une seringue préremplie | FT |
| VUTRISIRAN SODIQUEsolution | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.